ACET Adicet: Forward P/S Multiple
The GURU.Markets terminal displays a chart of the projected P/S ratio for Adicet Bio (ACET), where the metric level stands at 10.80. This price action reflects a strategic business pivot toward the therapy of autoimmune pathologies. Market confidence is bolstered by the leadership's authoritative scientific background and the transparency of FDA reports. High scalability potential coupled with low production costs per dose confirms the global growth prospects of the asset.
Summary analytical data breakdowns for adicetbio.com (ACET)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
- financial results and valuation multiples details:
ACET - Company Net Income|Projected Future Earnings Adicet Bio|ACET - Business Payback Period|Future Price to Earnings Adicet Bio, Inc.|ACET - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Adicet Bio, Inc.|ACET - Operating profit EBITDA|Net earnings per share (EPS TTM) Adicet Bio|ACET - Net earnings per share for the last 12 months|Quarterly EPS earnings growth adicetbio.com|ACET - Earnings per share growth rate in current year|Expected earnings per share growth for next year Adicet Bio
- sales and revenue indicators:
Initial company analysis:Adicet (ACET)
Forward P/S measures market value dynamics relative to expected sales volume, allowing for an assessment of demand stability for shares without confirmation from trading volumes. By analyzing the forward P/S metric on the GURU.Markets platform, an investor determines the risk of asset overvaluation for Adicet Bio (ACET) during the transition to automated T-cell therapy production, where the elimination of manual media contamination directly impacts future revenue.
Competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA - Forward P/S Multiple|PTGX: Forward P/S Multiple|Market Cap to Projected Revenue IMVT|KNSA (Kiniksa) - Forward P/S Multiple|Grifols SA (GRFS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ADPT|Forward Price-to-Revenue Multiple Celldex Corp CLDX|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Market Cap to Future Revenue Ratio|VERA: Forward Price-to-Revenue Multiple|Dianthus Therapeutics Inc - Price to Expected Revenue Ratio|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PGEN|Forward P/S Multiple PHAR|Market Cap to Expected Sales Ratio Nektar Therapeutics Inc|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Zenas Corp (ZBIO) - Market Cap to Future Revenue Ratio|Immunome, Inc. - Forward P/S Multiple|GOSS - Forward P/S Multiple|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Savara Pharma SVRA|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|Price to Expected Revenue Ratio ANAB|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT Therapeutics, Inc. - Forward P/S Multiple|Forward Price to Sales JBIO (Aerovate Therapeutics Inc)|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|CABA: Forward Price to Sales|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward P/S Multiple eledon.com ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio Inc.)|ZURA: Forward P/S Multiple|ATYR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Forward Price-to-Revenue Multiple Ikena Oncology, Inc. (IMA)|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Connect Biopharma Holdings Limited - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|IFRX (InflaRx N.V.) - Market Cap to Projected Revenue|XFOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio Celularity (CELU)|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward P/S Multiple Barinthus Biotherapeutics Corp|Forward P/S Multiple KZR|sabbiotherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Market Cap to Expected Sales Ratio Enlivex Therapeutics Ltd (ENLV)|Q32 Bio Corp - Forward P/S Multiple|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|Forward Price-to-Revenue Multiple CARM|XTLB (XTL Biopharmaceuticals Ltd) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple BOLT (Bolt Biotherapeutics)|HCWB (hcwbiologics.com) - Forward Price to Sales|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. - Price-to-Projected Revenue Ratio|Aditxt Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Forward P/S Multiple SCNI|Forward Price-to-Revenue Multiple calcimedica.com CALI|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc (ALLK) - Market Cap to Future Revenue Ratio|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Future Price to Revenue OCEA (Ocean Biomedical Inc)|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|THRD: Forward Price to Sales
